HC Wainwright Equities Analysts Increase Earnings Estimates for Celldex Therapeutics, Inc. (NASDAQ:CLDX)

Celldex Therapeutics, Inc. (NASDAQ:CLDX) – Investment analysts at HC Wainwright raised their Q2 2024 EPS estimates for Celldex Therapeutics in a report released on Tuesday, May 7th. HC Wainwright analyst J. Pantginis now expects that the biopharmaceutical company will earn ($0.59) per share for the quarter, up from their prior estimate of ($0.67). HC Wainwright currently has a “Buy” rating and a $80.00 price target on the stock. The consensus estimate for Celldex Therapeutics’ current full-year earnings is ($2.85) per share. HC Wainwright also issued estimates for Celldex Therapeutics’ Q3 2024 earnings at ($0.60) EPS, Q4 2024 earnings at ($0.60) EPS, FY2024 earnings at ($2.34) EPS and FY2025 earnings at ($2.67) EPS.

Celldex Therapeutics (NASDAQ:CLDX) last issued its earnings results on Monday, February 26th. The biopharmaceutical company reported ($0.57) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.76) by $0.19. Celldex Therapeutics had a negative return on equity of 41.06% and a negative net margin of 2,054.46%. The firm had revenue of $4.13 million for the quarter, compared to analysts’ expectations of $1.20 million.

Other equities research analysts have also recently issued research reports about the stock. Cantor Fitzgerald restated an “overweight” rating and issued a $67.00 price target on shares of Celldex Therapeutics in a research report on Friday, March 22nd. Guggenheim upped their price objective on Celldex Therapeutics from $72.00 to $90.00 and gave the company a “buy” rating in a research report on Tuesday, February 27th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $66.00.

Celldex Therapeutics Price Performance

NASDAQ:CLDX opened at $41.21 on Thursday. The company has a market cap of $2.30 billion, a price-to-earnings ratio of -14.16 and a beta of 1.60. Celldex Therapeutics has a 1 year low of $22.11 and a 1 year high of $53.18. The stock’s 50 day simple moving average is $41.71 and its two-hundred day simple moving average is $37.03.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Bank of New York Mellon Corp boosted its stake in Celldex Therapeutics by 1.5% in the 3rd quarter. Bank of New York Mellon Corp now owns 164,157 shares of the biopharmaceutical company’s stock worth $4,518,000 after purchasing an additional 2,408 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its position in Celldex Therapeutics by 36.1% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,582 shares of the biopharmaceutical company’s stock worth $181,000 after buying an additional 1,746 shares during the last quarter. TD Asset Management Inc boosted its holdings in shares of Celldex Therapeutics by 100.0% in the 3rd quarter. TD Asset Management Inc now owns 64,922 shares of the biopharmaceutical company’s stock valued at $1,787,000 after acquiring an additional 32,461 shares during the last quarter. Allspring Global Investments Holdings LLC increased its stake in shares of Celldex Therapeutics by 70.9% in the third quarter. Allspring Global Investments Holdings LLC now owns 1,941 shares of the biopharmaceutical company’s stock worth $53,000 after acquiring an additional 805 shares during the period. Finally, Teacher Retirement System of Texas boosted its holdings in Celldex Therapeutics by 4.8% in the third quarter. Teacher Retirement System of Texas now owns 11,400 shares of the biopharmaceutical company’s stock valued at $314,000 after purchasing an additional 522 shares during the last quarter.

About Celldex Therapeutics

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.